Due to open in 2026, TRI’s Translational Manufacturing facility will provide the necessary infrastructure to enable MedTech and BioTech businesses to mature and scale-up their manufacturing on Australian shores. It will attract a range of industry, from local start-ups and SMEs to international biomedical companies, delivering the first Australian facility to provide access to GMP facilities.
Discover the benefits of basing your business at Australia’s largest end-to-end translational research facility.
Sign up to stay informed and register your interest.
